nivolumab,ipilimumab
bms
['checkmate 914', 'ipilimumab', 'nivo', 'kcsm,(-skcsm)', 'check,mate,914', 'nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)']
adjuvant nivolumab + ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part a of the phase 3 checkmate 914 trial. #rcc #kcsm #esmo2022 
Oncology news and insights from leading researchers and cancer centers.